Kiniksa Pharmaceuticals Ltd Cash Flow-to-Debt Ratio
Kiniksa Pharmaceuticals Ltd cash flow-to-debt ratio. Kiniksa Pharmaceuticals Ltd (KNSA) has a Cash Flow-to-Debt Ratio of 0.20x as of June 2026, meaning its operating cash flow of $47.46 Million could theoretically repay 0% of its total liabilities ($241.96 Million) in one year. Check Kiniksa Pharmaceuticals Ltd (KNSA) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Kiniksa Pharmaceuticals Ltd (2016–2025)
Cash flow-to-debt ratio of Kiniksa Pharmaceuticals Ltd from 2016 to 2025. Historical debt coverage capacity for Kiniksa Pharmaceuticals Ltd across 10 annual periods. Check KNSA capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Kiniksa Pharmaceuticals Ltd Cash Flow-to-Debt Ratio by Year (2016–2025)
Kiniksa Pharmaceuticals Ltd cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Kiniksa Pharmaceuticals Ltd. For the full cash flow conversion analysis, see Kiniksa Pharmaceuticals Ltd cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.13x | $25.69 Million | $196.03 Million | ▼ -27.5% |
| 2024 | 0.18x | $25.69 Million | $142.12 Million | ▲ +18.9% |
| 2023 | 0.15x | $13.30 Million | $87.48 Million | ▲ +66.3% |
| 2022 | 0.09x | $5.81 Million | $63.52 Million | ▲ +103.5% |
| 2021 | -2.64x | $-126.30 Million | $47.76 Million | ▲ +27.3% |
| 2020 | -3.64x | $-136.53 Million | $37.53 Million | ▲ +33.1% |
| 2019 | -5.44x | $-158.37 Million | $29.11 Million | ▼ -186.7% |
| 2018 | -1.90x | $-81.01 Million | $42.70 Million | ▼ -418.4% |
| 2017 | -0.37x | $-50.22 Million | $137.20 Million | ▼ -37.6% |
| 2016 | -0.27x | $-21.87 Million | $82.20 Million | — |